Proteros has established a profitable discovery service business with a best-in-class enabling technology platform for structure accelerated lead discovery. Our track record is proven by an outstanding project success rate. Proteros’ proprietary pipeline includes highly disease relevant target classes such as kinases, epigenetic targets and GPCRs. Our success is built on unique know how and expertise in understanding the role of protein structures involved in protein and small molecule interactions that are responsible for the pathogenesis of many diseases.
The company was co-founded in 1999 by Nobel Laureate Prof. Robert Huber, a pioneer in structural biology, and CEO Dr. Torsten Neuefeind. Supported by a world-class team of over 65 scientists, the company has established a profitable lead discovery business serving 18 of the 20 largest pharmaceutical companies and over 70 clients from industry and academia, worldwide. On behalf its clients Proteros has been solving close to 400 structures per annum and elucidated 1,200 protein-ligand structures on more than 150 different targets in just the last 4 years.
The unique integration of Protein Biochemistry, Protein Crystallography, Biophysics and Medicinal Chemistry at Proteros allows the design and delivery of high quality lead compounds and structures for even the most demanding targets. Proteros is headquartered in state-of the-art facilities at the Martinsried biotech cluster, Munich, Germany.